BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24719326)

  • 1. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
    Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
    J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
    Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
    Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
    Pilzer D; Fishelson Z
    Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
    Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
    J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
    Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
    Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
    Pilzer D; Saar M; Koya K; Fishelson Z
    Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
    Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
    Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of complement C5b-9 binding to cells by flow cytometry.
    Moskovich O; Fishelson Z
    Methods Mol Biol; 2014; 1100():103-8. PubMed ID: 24218253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The killer molecule of complement.
    Müller-Eberhard HJ
    J Invest Dermatol; 1985 Jul; 85(1 Suppl):47s-52s. PubMed ID: 3891882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
    Kontermann R; Deppisch R; Rauterberg EW
    Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium.
    Joiner KA; Tartanian AB; Hammer CH; Schweinle JE
    J Immunol; 1989 Jun; 142(12):4450-7. PubMed ID: 2656866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.
    Podack ER; Tschoop J; Müller-Eberhard HJ
    J Exp Med; 1982 Jul; 156(1):268-82. PubMed ID: 6177822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.
    Taylor RP; Lindorfer MA; Cook EM; Beurskens FJ; Schuurman J; Parren PWHI; Zent CS; VanDerMeid KR; Burack R; Mizuno M; Morgan BP
    Clin Immunol; 2017 Aug; 181():24-28. PubMed ID: 28578024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmembrane channel-formation by five complement proteins.
    Müller-Eberhard HJ
    Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement.
    Zalman LS; Müller-Eberhard HJ
    Mol Immunol; 1990 Jun; 27(6):533-7. PubMed ID: 1696352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.
    Fu X; Ju J; Lin Z; Xiao W; Li X; Zhuang B; Zhang T; Ma X; Li X; Ma C; Su W; Wang Y; Qin X; Liang S
    Sci Rep; 2016 Jul; 6():30239. PubMed ID: 27444648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition.
    Martin DE; Chiu FJ; Gigli I; Müller-Eberhard HJ
    J Clin Invest; 1987 Jul; 80(1):226-33. PubMed ID: 3597774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.